Skip to main content

Advertisement

Table 2 Univariate analysis of prognostic factors for overall survival (OS) and progression-free survival (PFS) of patients with DLBCL

From: Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study

Variable 5-year OS rate (%) P value 5-year PFS rate (%) P value
Age (years)   < 0.01   0.02
 ≤ 60 66.7   54.7  
 > 60 42.1   38.8  
Clinical stage   < 0.01   < 0.01
 I–II 68.2   61.7  
 III–IV 50.7   38.4  
B symptoms   0.02   < 0.01
 No 63.8   54.2  
 Yes 48.7   38.7  
Spleen involvement   0.01   < 0.01
 No 62.4   53.0  
 Yes 41.8   31.4  
IPI   < 0.01   < 0.01
 < 3 64.4   55.6  
 ≥ 3 41.9   29.6  
LDH (U/L)   < 0.01   < 0.01
 ≤ 245 72.7   60.1  
 > 245 46.2   39.0  
β2-MG (mg/L)   < 0.01   0.07
 ≤ 2.52 73.2   54.6  
 > 2.52 42.2   35.7  
Rituximab   0.04   0.20
 Without 53.1   46.4  
 With 71.9   58.4  
First-line chemotherapy CR   < 0.01   0.04
 No 49.1   45.9  
 Yes 72.2   57.2  
PD-L1 expression in tumor cells   0.02   0.01
 Negative 67.3   59.6  
 Positive 50.0   39.6  
PD-L1 expression in tumor microenvironment   0.21   0.26
 Negative 62.0   52.5  
 Positive 48.9   39.3  
  1. IPI international prognostic index, LDH lactate dehydrogenase, β2-MG β2-microglobulin, CR complete remission, PD-L1 programmed cell death-ligand 1